Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 88 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 How serendipity sent this oncologist in search of a cure for... August 12, 2022 New Way to Classify Meningioma Brain Tumors Suggests Potential Treatments June 17, 2022 Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated,... January 30, 2026 Load more HOT NEWS How Breast Cancer Risk Assessment Tools Work Making the most of your ‘eureka’ moment: getting from the science... What Cancer Caregivers Should Know About Hospice Care at Home: A... Cancer in My Community: Addressing Health Disparities in Brazil
